Skip to main content
StemCell Institute logo

StemCell Institute — Investor Relations & Filings

Ticker · 7096 ISIN · JP3399640006 T Human health and social work activities
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-05-20 Board/Management Inform…
Country JP Japan
Listing T 7096

About StemCell Institute

https://www.stemcell.co.jp/en/

StemCell Institute Inc. is a private cord blood bank established in 1999. The company specializes in the collection, processing, and long-term cryopreservation of stem cells from umbilical cord blood and umbilical cord tissue. Its services are targeted at expectant parents who wish to store these biological materials for potential future use in regenerative medicine and cell therapies for their child or family members. The company operates a state-of-the-art cell processing center and a large-scale cryopreservation facility. It is the largest private cord blood bank in its domestic market, holding over 99% market share and storing more than 80,000 units. StemCell Institute is the only private bank in its region to have released stored units for clinical applications, including treatments for conditions such as leukemia and cerebral palsy. The company is ISO 9001 certified.

Recent filings

Filing Released Lang Actions
取締役及び補欠監査役の候補者選任に関するお知らせ
Board/Management Information Classification · 90% confidence The document is an announcement of the board’s resolution regarding the nomination of director and audit & supervisory board candidates for approval at the upcoming annual shareholders’ meeting. It lists candidates, their positions, and backgrounds. This clearly falls under an announcement of changes in the company’s board of directors and audit & supervisory board, matching the Board/Management Information category.
2026-05-20 Japanese
ストック・オプション（新株予約権）の発行に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a formal corporate announcement by 株式会社ステムセル研究所 regarding the issuance of stock acquisition rights (stock options) to directors, officers, employees and subsidiary employees. It contains detailed terms of the stock option plan (number of shares, exercise price calculation, adjustment events, exercise period, etc.). This is not a full financial report, audit, or proxy material but a notification of a capital change (issuance of new share-related instruments). Under the classification scheme, announcements about new share issues, stock splits or other changes to capital structure fall under Share Issue/Capital Change (SHA).
2026-05-20 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Purchase of Own Shares' (自己株券買付状況報告書) filed under the Financial Instruments and Exchange Act in Japan. It details the company's share repurchase activity, including the number of shares acquired and the total cost, which directly corresponds to the 'Transaction in Own Shares' (POS) category.
2025-12-01 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically related to the accuracy of a semi-annual report. In the Japanese regulatory context, this is a standard filing accompanying financial reports to confirm the validity of the contents. Since it is a specific regulatory filing required by law and does not fit into the other categories like 'Annual Report' or 'Interim Report' (as it is a confirmation statement, not the report itself), it falls under the 'Regulatory Filings' (RNS) category.
2025-11-14 Japanese
半期報告書－第27期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by StemCell Institute Inc. in Japan. It contains detailed financial statements, management analysis (MDA), and audit information for the interim period ending September 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. H1 2026
2025-11-14 Japanese
自己株券買付状況報告書（法２４条の６第１項に基づくもの）
Transaction in Own Shares Classification · 100% confidence The document is a '自己株券買付状況報告書' (Report on Status of Acquisition of Treasury Shares) filed under the Financial Instruments and Exchange Act. It details the company's share buyback activity for the period of October 2025. This specific type of regulatory filing regarding the company's own share transactions falls directly under the 'Transaction in Own Shares' category.
2025-11-04 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.